Current Research Studies
Cancer – AALL1931: An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. coli-derived Asparaginases
Condition or Therapy:
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Category:
Cancer and Blood Disorders
Study Number: AALL1931
What is the goal of this study?
The aim of this study is to learn more about the pharmacology of the drug RC-P, including its side effects.
Who can join the study?
This study may be a good fit for children and young adults who:
- Have been diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.
Study Location(s):
Seattle Children's Main Hospital Campus
Principal Investigator:
Dr. Kasey Leger
Research Center: Center for Clinical and Translational Research